Use of a Cystatin C-Based GFR Equation in a Population Pharmacokinetic Model of Methotrexate Clearance in Adult Patients with Lymphoma

Key Points

• Early sampling of methotrexate concentrations supports reducing acute kidney injury risk during therapy.
• Cystatin C-inclusive estimates enhance accuracy for glomerular filtration rate calculations in pharmacokinetics.
• Using cystatin C helps identify patients at risk of acute kidney injury during high-dose methotrexate therapy.
• These findings highlight the potential for proactive clinical interventions based on pharmacokinetic models.